The Key to Cholangiocarcinoma Treatment Lies in SERPINE1

Cholangiocarcinoma, a rare but highly aggressive cancer of the bile ducts, represents one of the most challenging battles in the fight against cancer. This stealthy disease often goes undetected until it reaches an advanced stage, making it difficult to treat and leading to a poor prognosis for many patients. As the complex environment surrounding these tumors is explored further, hidden forces that allow cholangiocarcinoma to thrive and resist treatment are being uncovered. At the heart of this discovery is a protein that could hold the key to new, more effective therapies.

Researchers from Albany Medical College, led by Professor Paul Higgins and in collaboration with Dr. Ralf-Peter Czekay, Dr. Hasan Aydin, Dr. Rohan Samarakoon, Dr. Nusret Subasi, Dr. Hwajeong Lee, Craig Higgins and Stephen Higgins, recently reviewed current data to provide crucial insights into the role of SERPINE1 in the progression of cholangiocarcinoma (CCA). Their study, published in Cells, sheds light on how the tumor microenvironment (TME) in CCA is shaped by cancer-associated fibroblasts (CAFs) and how this, in turn, drives tumor progression and resistance to treatment.

The researchers emphasize that the desmoplastic reaction—a process involving the accumulation of a dense, fibrotic matrix around the tumor—is a key factor in the poor prognosis and resistance to chemotherapy seen in cholangiocarcinoma. Within this fibrotic environment, CAFs play a central role by remodeling the extracellular matrix (ECM), promoting tumor cell survival, and fostering a milieu conducive to cancer growth and spread.

SERPINE1, a gene that encodes plasminogen activator inhibitor-1 (PAI-1), is identified as a significant player in this process. The study reveals that PAI-1 is heavily involved in ECM remodeling, enhancing the fibrotic nature of the TME. PAI-1 not only supports the physical structure of the tumor’s surroundings but also contributes to cancer cell invasion, metastasis, and resistance to cell death. “PAI-1’s multifunctional role in CCA progression makes it a potential therapeutic target, especially given its contribution to the aggressive and drug-resistant nature of these tumors,” explained Professor Higgins in a discussion about the findings.

The team explored the complex signaling pathways that facilitate the interplay between CAFs and tumor cells. The TGF-β pathway, particularly through its interaction with SERPINE1, was highlighted as a major driver of the desmoplastic reaction in CCA. This pathway not only enhances the fibrotic environment but also promotes the stemness and plasticity of cancer cells, making them more adaptable and resistant to therapies.

In an effort to disrupt this harmful interaction, the study suggests that targeting PAI-1 or its associated pathways could prove beneficial. Experimental knockdown of PAI-1 in cholangiocarcinoma cells led to a significant reduction in cell motility, indicating that inhibiting PAI-1 could potentially slow down or prevent the spread of the cancer. “Our findings suggest that targeting PAI-1 in the tumor microenvironment could offer a new therapeutic approach for treating cholangiocarcinoma, particularly in cases where the tumor is resistant to conventional therapies,” added Professor Higgins.

This research by Professor Higgins and his colleagues not only enhances our understanding of the molecular mechanisms driving cholangiocarcinoma but also opens new avenues for therapeutic intervention. By targeting the components of the TME that facilitate tumor growth and resistance, their work offers the potential to improve outcomes for patients suffering from this challenging disease.